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ABSTRACT
Sporadic colorectal cancer (CRC) is characterized by genetic and epi-
genetic changes such as regional DNA hypermethylation and global DNA
hypomethylation. Epidemiological and animal studies suggest that aber-
rant DNA methylation is associated with low dietary folate intake, which
is aggravated by high alcohol intake. The relationship between promoter
methylation of genes involved in CRC carcinogenesis and folate and
alcohol intake was investigated. Methylation of the APC-1A, p14ARF,
p16INK4A, hMLH1, O6-MGMT, and RASSF1A promoters was studied using
methylation-specific PCR in 122 sporadic CRCs, derived from patients
with folate and alcohol intake at either the lower or the higher quintiles of
the distribution. Overall, promoter hypermethylation frequencies ob-
served were: 39% for APC; 33% for p14ARF; 31% for p16INK4A; 29% for
hMLH1; 41% for O6-MGMT; and 20% for RASSF1A. For each of the
tested genes, the prevalence of promoter hypermethylation was higher in
CRCs derived from patients with low folate/high alcohol intake (n  61)
when compared with CRCs from patients with high folate/low alcohol
intake (n  61), but the differences were not statistically significant. The
number of CRCs with at least one gene methylated was higher (84%) in
the low folate intake/high alcohol intake group when compared with the
high folate intake/low alcohol intake group (70%; P  0.085). Despite the
size limitations of this study, these data suggest that folate and alcohol
intake may be associated with changes in promoter hypermethylation
in CRC.
INTRODUCTION
In addition to hereditary components, known risk factors for CRC3
are related to lifestyle and environment such as smoking and a
Western diet (high meat, energy, and alcohol intake and low fruit,
vegetable, and fiber intake; Ref. 1). Although the majority of epide-
miological studies point to fruit and vegetable intake as protective for
CRC (2–11), the molecular mechanisms for this protection remain to
be clarified. It is hypothesized that folate, one of the vitamins mainly
found in green leafy vegetables, is in part responsible for the inverse
association with CRC risk. The effects of low folate intake are
aggravated by high alcohol intake (7), probably because of degrada-
tion of folate in the colon by acetaldehyde, the first metabolite of
alcohol (12).
Folate, as 5-methyltetrahydrofolate, has a central role in methyl
metabolism. It supplies a methyl group to convert homocysteine to
methionine, which is then converted to S-adenosylmethionine, the
universal methyl donor for methylation of a wide variety of biological
substrates such as DNA, RNA, and proteins. Folate deficiency is
reported to be associated with the occurrence of point mutations in
K-ras in colorectal adenomas (13) and carcinomas (14), single and
double strand DNA breaks, chromosome breakage (15, 16), and
global DNA hypomethylation (17).
Although the overall level of genomic methylation is actually
reduced in certain tumor types, including CRCs (18, 19), hypermethy-
lation at several gene promoters has also been reported. It has been
hypothesized that global hypomethylation might induce regional de
novo hypermethylation (20). On the other hand, a recent study by
Bariol et al. (21) suggests that there is no relationship between global
demethylation and regional hypermethylation in CRC.
To investigate whether altered DNA methylation is associated with
folate and alcohol intake, we examined promoter methylation of genes
that have been reported to be involved and methylated in CRC
carcinogenesis, i.e., APC-1A, p14ARF, p16INK4A, hMLH1, O6-MGMT,
and RASSF1A (22, 23). This was done using an optimized MSP
method. This study was performed with 122 CRC archival specimens
derived from incident cases who participate in the prospective NLCS
(24). Patients with low folate intake in addition to high alcohol intake
at baseline (n  61) were compared with patients with high folate
intake in addition to low alcohol intake (n  61) with respect to the
methylation status of a series of gene promoters.
MATERIALS AND METHODS
Study Population and Sample Procurement. The paraffin-embedded
CRC samples used in this study were derived from patients who participate in
NLCS. This study started in September 1986 and included 58,279 men and
62,573 women (55–69 years at baseline). At baseline, the cohort members
completed a mailed, self-administered food frequency questionnaire on dietary
habits and other risk factors for cancer. The study design has been described
in detail elsewhere (24). Follow-up for incident cancer is established annually
by computerized record linkage with all cancer registries in the Netherlands
and with PALGA, a nationwide pathology database (25). Since 1989, the
coverage of PALGA is 100% (26). Record linkage covering the period from
1989 up to the end of 1993 (7.3 years follow-up, with exclusion of the first 2.3
years of follow-up) resulted in 819 eligible incident, histologically confirmed
CRC patients. After approval by the Medical Ethical Committee of the Maas-
tricht University and PALGA, tissue samples were collected from 54 pathol-
ogy laboratories throughout the Netherlands. Tumor tissue sample collection
was started in August 1999 and was completed in December 2001.
For this pilot study, 61 CRCs of patients with high methyl donor intake
[high folate intake (215 g/day) in addition to extremely low alcohol intake
(0–4 g/day)] and 61 CRCs of patients with low methyl donor intake [folate
intake (215 g/day) in addition to high alcohol intake (5 g/day)] were
selected (for selection criteria and definitions; Table 1). Among the selected
patients were 68 males and 54 females (58–76 years of age at time of
diagnosis), 30 Dukes A, 39 Dukes B, 31 Dukes C, and 15 Dukes D CRCs.
Dukes stage was not reported in 7 cases. The distribution of the location of the
tumors was colon (n  84), rectosigmoid (n  14), and rectum (n  24). The
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122 patients in this study were representative for the complete group of eligible
CRC patients with respect to age, gender, Dukes stage, and tumor location
distribution.
After identification by a pathologist (A. P. d. B.), genomic DNA of tumor
cells was microdissected and extracted using proteinase K (Qiagen) and the
Puregene DNA Isolation Kit (Gentra Systems) and stored at 4°C. Part of this
set of samples has previously been characterized for RASSF1A promoter
methylation (23).
Food Frequency Questionnaire. At the start of the NLCS in 1986, all
participants completed a food frequency questionnaire on daily food consump-
tion and potential confounders (e.g., smoking, occupation, physical activity,
family history of cancer, drug use). The dietary section of the questionnaire, a
150-item semiquantitative food frequency questionnaire, concentrated on ha-
bitual consumption of food and beverages during the year preceding the start
of the study. The questionnaire was validated against a 9-day dietary record.
Daily mean nutrient intakes are calculated using the computerized Dutch food
composition table. Folate intake was calculated from newly established liquid
chromatography data for foods (27).
Questionnaire data of all cases and the subcohort are key-entered twice and
processed in a manner blinded with respect to case/subcohort status to mini-
mize observer bias in coding and interpreting the data. Both procedures make
use of a highly standardized protocol. Subjects with incomplete or inconsistent
dietary data are excluded from data analysis, according to criteria described in
detail elsewhere (28). Patients with low folate intake in addition to high alcohol
intake were defined as the low methyl donor group, whereas patients with high
folate intake in addition to low alcohol intake were defined as the high methyl
donor group (Table 1). Dietary factors adjusted for in data analyses are chosen
on the basis of a previous analysis on the association between folate and
CRC (2).
Promoter Methylation Analysis. DNA methylation in the CpG islands of
the APC-1A, p14ARF, p16INK4a, hMLH1, O6-MGMT, and RASSF1A gene pro-
moters was determined by chemical modification of genomic DNA with
sodium bisulfite and subsequent MSP as described in detail elsewhere (29). In
brief, 1 g of DNA was denatured by NaOH and modified by sodium bisulfite.
DNA samples were then purified using Wizard DNA purification resin (Pro-
mega), again treated with NaOH, precipitated with ethanol, and resuspended
in H2O.
To facilitate MSP analysis on DNA retrieved from formalin-fixed, paraffin-
embedded tissue, DNA was first amplified with flanking PCR primers that
amplify bisulfite-modified DNA but do not preferentially amplify methylated
or unmethylated DNA. The resulting fragment was used as a template for the
MSP reaction.
All PCRs were performed with controls for unmethylated alleles (DNA
from normal lymphocytes), methylated alleles [normal lymphocyte DNA
treated in vitro with SssI methyltransferase (New England Biolabs)], and a
control without DNA. Primer sequences and PCR conditions are described in
Table 2. Ten l of each MSP reaction were directly loaded onto nondenaturing
6% polyacrylamide gels, stained with ethidium bromide, and visualized under
UV illumination. To study the reproducibility of the nested MSP approach,
duplicate CRC specimens were analyzed. Reproducibility was 95%.
Data Analysis. Frequencies of promoter methylation of specific genes and
frequencies and means of other variables in patients with high and low methyl
donor intake were computed. Differences in frequencies of variables were
tested using the 2 test, and differences in mean levels of variables were tested
using the t test. Logistic regression analyses were performed to test whether
there was a difference in methyl donor intake (low versus high) between CRCs
with at least one gene methylated versus no genes methylated while adjusting
for potential confounders. Because nine categories of methyl-donor intake
were distinguished (categories 1 through 9 in Table 1), although only based on
extreme levels of intake, logistic regression analyses were also performed
including this variable instead of the dichotomous intake variable in the model.
A P of 0.05 was considered to be statistically significant. All tests of statistical
significance were two-sided. Data analysis was done using SPSS software
(version 9.0).
RESULTS
To enable MSP analysis on DNA retrieved from formalin-fixed,
paraffin-embedded tumor tissue, nested MSP was performed. Nested
Table 1 Selection of CRC patients based on extreme intakes of folate and alcohol
intake (quintile distribution)
Methyl donor group
(dichotome)
Quintile
combinationa
Methyl donor
category
Folate intake
(g/day)
Alcohol
intake (g/day) n
Low folate/high
alcohol (n  61)
F1/A5 1 0–157 30 7
F1/A4 2 0–157 15–29 14
F1/A3 3 0–157 5–14 15
F2/A5 4 158–186 30 16
F2/A4 5 158–186 15–29 6
F3/A5 6 187–215 30 3
High folate/low
alcohol group
(n  61)
F4/A1 7 215–255 0 19
F5/A2 8 255 0.1–4 24
F5/A1 9 255 0 18
a Quintiles of folate (F) and alcohol (A) intake; i.e., F1/A5 is first quintile of folate and
fifth quintile of alcohol.
Table 2 MSP primer sequences and PCR conditions
Primer set Sense primer Antisense primer
Amp Size
(bp)
Annealing
temperature (°C)
No. of PCR
cycles
APC-1A flank 5-TGGGYGGGGTTTTGTGTTTTATT-3 5-TACRCCCACACCCAACCAATC-3 136 56 35
APC-1A Ua 5-GTGTTTTATTGTGGAGTGTGGGTT-3 5-CCAATCAACAAACTCCCAACAA-3 108 60 25
APC-1A M 5-TATTGCGGAGTGCGGGTC-3 5-TCGACGAACTCCCGACGA-3 98 60 25
p14ARF flank 5-TTTAGTTTGTAGTTAAGGGGGTAGGAG-3 5-CRCTACCCACTCCCCCRTAAACC-3 207 56 35
p14ARF flank short 5-GYGTTGTTTATTTTTGGTGTTAAAGG-3 5-AAATATAAACCACRAAAACCCTCACT-3 152 56 35
p14ARF U 5-TTTTTGGTGTTAAAGGGTGGTGTAGT-3 5-CACAAAAACCCTCACTCACAACAA-3 132 60 25
p14ARF M 5-GTGTTAAAGGGCGGCGTAGC-3 5-AAAACCCTCACTCGCGACGA-3 122 60 25
p16INK4a flank 5-AGAAAGAGGAGGGGTTGGTTGG-3 5-ACRCCCRCACCTCCTCTACC-3 193 56 35
p16INK4a flank short 5-GGGTTGGTTGGTTATTAGAGGGT-3 5-RACCRTAACCAACCAATCAACC-3 148 56 35
p16INK4a U 5-TTATTAGAGGGTGGGGTGGATTGT-3 5-CAACCCCAAACCACAACCATAA-3 151 60 30
p16INK4a U short 5-GTTGGTTATTAGAGGGTGGGGTGGATTGT-3 5-AACCAAAAACTCCATACTACTCCCCACCA-3 124 62 25
p16INK4a M 5-TTATTAGAGGGTGGGGCGGATCGC-3 5-GACCCCGAACCGCGACCGTAA-3 150 60 30
p16INK4a M short 5-TTATTAGAGGGTGGGGCGGATCGC-3 5-GAAAACTCCATACTACTCCCCGCCG-3 115 62 25
O6-MGMT flank 5-GYGTTTYGGATATGTTGGGATAGTT-3 5-AAACTCCRCACTCTTCCRAAAAC-3 135 56 35
O6-MGMT U 5-TTTGTGTTTTGATGTTTGTAGGTTTTTGT-3 5-AACTCCACACTCTTCCAAAAACAAAACA-3 93 60 30
O6-MGMT M 5-TTTCGACGTTCGTAGGTTTTCGC-3 5-GCACTCTTCCGAAAACGAAACG-3 81 60 30
hMLH1 flank 5-GGAGTGAAGGAGGTTAYGGGTAAGT-3 5-AAAAACRATAAAACCCTATACCTAATCTATC-3 182 56 35
hMLH1 flank short 5-TTTTGAYGTAGAYGTTTTATTAGGGT-3 5-AAAACRATAAAACCCTATACCTAATCTATC-3 154 56 35
hMLH1 U 5-TTTTGATGTAGATGTTTTATTAGGGTTGT-3 5-ACCACCTCATCATAACTACCCACA-3 124 60 35
hMLH1 U short 5-TGTGTGTTTGTTGTTTGTTATATATTGTTT-3 5-ACCACCTCATCATAACTACCCACA-3 98 60 35
hMLH1 M 5-ACGTAGACGTTTTATTAGGGTCGC-3 5-CCTCATCGTAACTACCCGCG-3 115 60 35
hMLH1 M short 5-GTTCGTCGTTCGTTATATATCGTTC-3 5-CCTCATCGTAACTACCCGCG-3 89 60 35
RASSF1A flank 5-GTTTAGTTTGGATTTTGGGGGAG-3 5-CCCRCAACTCAATAAACTCAAACTC-3 144 56 35
RASSF1A U 5-GGGGTTTGTTTTGTGGTTTTGTTT-3 5-AACATAACCCAATTAAACCCATACTTCA-3 81 60 30
RASSF1A M 5-GGGTTCGTTTTGTGGTTTCGTTC-3 5-TAACCCGATTAAACCCGTACTTCG-3 76 60 30
a U, unmethylated DNA specific primers; M, methylated DNA specific primers.
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MSP analysis could easily be performed for APC-1A, O6-MGMT, and
RASSF1A, genes for which the designed MSP amplicons are relatively
small, i.e., 165 bp (see Table 2). However, using the flanking MSP
primers originally designed for p14ARF, p16INK4a, and hMLH1 (30),
the success rate for amplification decreased with increasing size of the
MSP amplicons. Bisulfite-treated DNA could not be amplified for
p14ARF (207 bp) in 18% (22 of 121), for p16INK4a (193 bp) in 12% (14
of 120), and for hMLH1 (182 bp) in 16% (20 of 123) of CRC cases.
To increase the MSP success rate, MSP primers for these promoter
regions were redesigned to obtain shorter amplicons (155 bp). Using
these primer sets, a subgroup of CRC cases (n  52), which did and
which did not amplify using the original MSP primer sets, were
amplified using the redesigned MSP primers. The MSP success rate
increased to 94% (49 of 52) for p14ARF, 90% (47 of 52) for p16INK4a,
and 100% (52 of 52) for hMLH1. The concordance between the
original and the redesigned short primer sets was tested and was found
to be 94% (31 of 33) for p16INK4a, 94% (30 of 32) for hMLH1, and
93% (25 of 27) for p14ARF. Because of the rate of concordance
between the different primer sets, data using both sets of primers were
pooled. Genes that showed methylation using only one of both primer
sets were considered as methylated.
Overall, promoter hypermethylation frequencies observed were:
39% (47 of 122) for APC-1A; 33% (40 of 120) for p14ARF; 31% (37
of 119) for p16INK4A; 29% (35 of 122) for hMLH1; 41% (50 of 121)
for O6-MGMT; and 20% (24 of 122) for RASSF1A (Table 3). Repre-
sentative examples of the MSP reactions are shown in Fig. 1.
For all genes, the prevalence of promoter hypermethylation was higher
in CRCs derived from patients with low methyl donor intake when
compared with CRCs from patients with high methyl donor intake,
however, none of these individual differences reached statistical signifi-
cance. The percentage of CRCs with at least one gene methylated versus
no gene methylated was higher (84%) in the low methyl donor intake
group when compared with the adequate/high methyl donor intake group
(70%; P  0.085; Table 3).
Dukes stage and location of the tumor did not differ between the
two groups of patients (Table 3). Age at diagnosis was higher in
patients with low methyl donor intake. There were significantly more
males in the low methyl donor intake group (67%) when compared
with the high methyl donor intake group (44%; P  0.011; Table 3).
Factors previously shown to be associated with folate intake, i.e.,
energy-, fiber-, vitamin C-, and iron intake (2), were all significantly
lower in patients with low methyl donor intake compared with pa-
tients with adequate/high methyl donor intake (Table 3).
Table 4 summarizes the Dukes stage, location of the tumor, age at
diagnosis and energy-, fiber-, vitamin C-, and iron intake, none of
which are associated with promoter methylation. Family history of
cancer frequency was higher (25%) in patients who had none of the
six studied genes methylated, compared with patients with at least one
gene methylated (13%), but the difference did not reach statistical
significance (Table 4). Table 4 also shows that gender is significantly
associated with promoter methylation (P  0.046). Sixty-one percent
of patients were male in the group with at least one gene methylated
versus 39% in the group with no genes methylated (Table 4). Caution
is warranted in interpretation because these results are based on a
selection of extreme intakes.
The OR for promoter methylation of at least one gene methylated
Table 3 Prevalence of promoter methylation, clinicopathological parameters and other patient characteristics for the total number of CRCs and for the high and low methyl
donor intake groups
Total
(n  122)
Methyl donor intake
PHigh (n  61) Low (n  61)
Methylation
Promoter methylation
APC 47/122 (39%) 20/61 (33%) 27/61 (44%) 0.193
p14ARF 40/120 (33%) 17/60 (28%) 23/60 (38%) 0.245
p16INK4 37/119 (31%) 18/59 (31%) 19/60 (32%) 0.891
hMLH1 35/122 (29%) 17/61 (28%) 18/61 (30%) 0.841
O6-MGMT 50/121 (41%) 22/61 (36%) 28/60 (47%) 0.236
RASSF1A 24/122 (20%) 9/61 (15%) 15/61 (25%) 0.172
Number of genes methylated
0 28/122 (23%) 18/61 (30%) 10/61 (16%)
1 25/122 (20%) 12/61 (20%) 13/61 (21%)
2 29/122 (24%) 13/61 (21%) 16/61 (26%)
3 18/122 (15%) 8/61 (13%) 10/61 (16%)
4 16/122 (13%) 9/61 (15%) 7/61 (12%)
5 4/122 (3%) 1/61 (2%) 3/61 (5%)
6 2/122 (2%) 0/61 (0%) 2/61 (3%) 0.411
At least 1 gene methylated 94/122 (77%) 43/61 (70%) 51/61 (84%) 0.085
Clinicopathological parameters
Dukes stagea
A 30 (26%) 17 (29%) 13 (23%)
B 39 (34%) 18 (30%) 21 (37%)
C 31 (27%) 13 (22%) 18 (32%)
D 15 (13%) 11 (19%) 4 (7%) 0.19
Location of tumor
Colon 84 (69%) 45 (74%) 39 (64%)
Rectosigmoid 14 (11%) 4 (7%) 10 (16%)
Rectum 24 (20%) 12 (20%) 12 (20%) 0.223
Proximal location (yes)b 75 (62%) 36 (60%) 39 (64%) 0.498
Other patient characteristics
Age at diagnosis (yr) 67.4 66.7 68.1 0.086
Gender (male) 68 (56%) 27 (44%) 41 (67%) 0.011
Family history of CRC (yes) 19 (16%) 9 (15%) 10 (16%) 0.803
Dietary factors
Energy intake (kcal) 1951 2105 1797 0.002
Fiber intake (g) 27 32.9 21.2 0.019
Vitamin C intake (mg) 107 135.1 79 0.001
Iron intake (mg) 12.7 14.6 10.8 0.022
a For 7 cases, Dukes stage is not reported.
b For 1 case, proximal/distal location was not determined.
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was 2.13 (95% CI, 0.89–5.11) for patients with low methyl donor
intake versus high methyl donor intake. Adjustment for age, sex,
energy-, fiber-, vitamin C-, and iron intake and family history of
cancer revealed an OR of 1.82 (95% CI, 0.49–6.78). When the methyl
donor intake variable with nine categories was modeled in a similar
way, a positive association with promoter methylation of at least one
gene was still observed, although not statistically significant (unad-
justed OR, 1.14, P  0.124; adjusted OR, 1.12, P  0.420).
DISCUSSION
A better understanding of the causality of CRC can be established
by combining epidemiology and research on molecular mechanisms.
Here, this approach was used to study whether dietary intake of folate
and alcohol is associated with hypermethylation of tumor suppressor-
and DNA repair genes in CRC specimens derived from the NLCS.
Nested MSP analysis was optimized, and as a result, almost all CRC
specimens, irrespective of the quality of the DNA, could be analyzed
for hypermethylation in the promoter regions of APC-1A, p14ARF,
p16INK4A, hMLH1, O6-MGMT, and RASSF1A. This optimized nested
MSP approach enables high throughput promoter methylation analy-
sis in archival, formalin-fixed and paraffin-embedded tissues for mo-
lecular epidemiology studies.
For p14ARF, p16INK4A, and O6-MGMT, the overall prevalence of
promoter methylation, i.e., 33, 31, and 41%, respectively, are in the
range of the prevalence reported for CRC (22, 31, 32). For RASSF1A,
the prevalence of promoter methylation was similar to the frequency
reported on a larger series of CRCs from the same cohort (23). For
APC-1A and hMLH1, the overall prevalence is higher than reported
thus far (30, 33). This difference might be because the CRC material
used in this study is obtained from patients from a different geo-
graphic area (the Netherlands) compared with the patient material
used in the other studies (United States).
Although not significant, our results indicate that methyl donor
deficiency is associated with overall methylation of multiple genes, an
effect which is stronger than the effect on specific promoter regions
itself. The association, although not statistically significant, between
the nine different categories of methyl donor intake and promoter
methylation of at least one gene supports this. However, these results
have to be interpreted with caution because only extreme categories
were used, and intermediate categories of methyl donor intake in this
pilot study were omitted. In addition, stratification of patients was
done primarily on folate intake and secondarily on alcohol intake.
Therefore, the conclusions of this study are based primarily on folate
intake. Other dietary factors of importance for methyl donor intake
(e.g., vitamins B6 and B12) were not accounted for in this selection of
patients.
Increasing the power of the study, including CRCs from patients
with the complete spectrum of folate and alcohol intake and analysis
of the effect of intake of other methyl donors such as vitamins B6 and
B12, will reveal whether the observed effects of methyl donor defi-
ciency is stable. In addition, it is necessary to study whether there is
effect modification by alcohol (as suggested with overall CRC in the
First National Health and Nutrition Examination Survey study; Ref. 7)
in the complete group of CRCs derived from the NLCS. Another
drawback of this study is that only case-case and not case-cohort
analyses were performed. Knowledge on global hypomethylation
status, which is hypothesized to occur previously to regional hyper-
methylation, would also be interesting to analyze with respect to
promoter hypermethylation. In addition, it is possible that the ob-
served effect of folate deficiency on promoter methylation will be
stronger after stratification for functionally important SNPs in genes
involved in folate metabolism. Methylenetetrahydrafolate reductase,
methionine synthase, and methionine synthase reductase are interest-
ing enzymes involved in the generation of S-adenosylmethionine, the
primary methyl donor for DNA methylation reactions. All three
enzymes have been reported to have common SNPs, which are asso-
ciated with enhanced thermolability and decreased enzyme activity.
The effect of the SNPs on colorectal and other cancer risks also seems
to be dependent on methionine, folate, vitamins B6 and B12, and
alcohol intake (34–40).
In conclusion, despite its limited size, this study suggests that
methyl donor intake is associated with an increased frequency of
promoter hypermethylation of genes involved in CRC carcinogenesis.
Fig. 1. Representative examples of APC-1A-,
O6-MGMT-, and hMLH1-nested MSP reactions of
six primary CRCs and controls. The presence of a
visible PCR product in those lanes marked U indi-
cates the presence of unmethylated alleles; the
presence of product in those lanes marked M indi-
cates the presence of methylated alleles. All CRCs
include amplification with the U primer set, prob-
ably a result of the presence of normal, contami-
nating tissue. Normal lymphocytes (NL) and in
vitro methylated DNA (IVD) were used as negative
and positive controls for APC-1A, O6-MGMT, and
hMLH1 promoter methylation, respectively. The
H2O control was included in the flanking PCR and
subsequently in the MSP reaction.
Table 4 Clinicopathological parameters and other patient characteristics in CRCs with
no genes versus at least one gene methylated
No genes methylated
(n  28)
At least one gene
methylated (n  94) P
Clinicopathological parameters
Dukes stage
A 7/26 (27%) 23/89 (26%)
B 10/26 (39%) 29/89 (33%)
C 4/26 (15%) 27/89 (30%)
D 5/26 (19%) 10/89 (11%) 0.412
Location of tumor
Colon 19/28 (68%) 65/94 (69%)
Rectosigmoid 2/28 (7%) 11/94 (12%)
Rectum 7/28 (25%) 18/94 (19%) 0.675
Proximal location (yes) 19/28 (68%) 56/93 (60%) 0.465
Other patient characteristics
Age at diagnosis (yr) 67.8 67.3 0.581
Gender (male) 11/28 (39%) 57/94 (61%) 0.046
Family history of cancer (yes) 7/28 (25%) 12/94 (13%) 0.117
Dietary factors
Energy intake (kcal) 1937 1955 0.854
Fiber intake (g) 28.6 26.6 0.274
Vitamin C intake (mg) 115 104 0.339
Iron intake (mg) 13.2 12.6 0.368
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